Published in J Clin Invest on September 28, 2015
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity (2016) 1.06
Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res (2016) 0.88
Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. Proc Natl Acad Sci U S A (2016) 0.82
T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal (2017) 0.78
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunol Rev (2017) 0.78
Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev (2017) 0.78
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res (2016) 0.76
Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression. PLoS One (2016) 0.75
TIGIT signaling pathway negatively regulates CD4(+) T cell responses in systemic lupus erythematosus. Immunology (2017) 0.75
Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection. JCI Insight (2017) 0.75
TIGIT and Helios Are Highly Expressed on CD4(+) T Cells in Sézary Syndrome Patients. J Invest Dermatol (2016) 0.75
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology (2017) 0.75
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol (2017) 0.75
Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation. Front Immunol (2017) 0.75
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open (2017) 0.75
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40(+) monocyte differentiation. J Hematol Oncol (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 12.67
T cell exhaustion. Nat Immunol (2011) 11.08
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol (2009) 8.32
Interleukin-10 determines viral clearance or persistence in vivo. Nat Med (2006) 8.01
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med (2001) 5.56
Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol (2007) 5.14
Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med (2006) 4.97
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (2012) 3.39
CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol (2005) 2.83
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol (2008) 2.34
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell (2014) 2.24
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother (2006) 2.20
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol (2004) 1.92
Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol (2011) 1.77
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.77
Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol (2009) 1.75
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity (2014) 1.57
Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med (2014) 1.40
Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol (2011) 1.36
TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology (2013) 1.22
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J Clin Invest (2015) 1.22
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Invest (2014) 1.13
Canonical Wnt signaling negatively modulates regulatory T cell function. Immunity (2013) 1.13
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol (2009) 1.09
T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling. J Biol Chem (2014) 0.96
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother (2009) 0.90
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. J Immunol (2015) 0.83
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Induction and effector functions of T(H)17 cells. Nature (2008) 7.75
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med (2007) 7.73
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature (2008) 7.00
Interleukin-17 and type 17 helper T cells. N Engl J Med (2009) 6.83
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 6.58
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol (2008) 6.41
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol (2008) 5.92
Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med (2004) 5.13
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol (2003) 5.07
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Th17: the third member of the effector T cell trilogy. Curr Opin Immunol (2007) 4.78
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature (2013) 4.74
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2010) 4.56
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
Induction and molecular signature of pathogenic TH17 cells. Nat Immunol (2012) 4.43
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 4.06
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96
Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol (2009) 3.88
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 3.70
Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol (2009) 3.49
CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol (2007) 3.39
Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol (2008) 3.37
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A (2009) 3.31
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13
IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 3.12
Dynamic regulatory network controlling TH17 cell differentiation. Nature (2013) 3.07
IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 3.04
IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood (2009) 3.04
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest (2013) 3.03
TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol (2005) 3.00
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A (2010) 2.88
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol (2005) 2.83
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest (2006) 2.75
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγt. Nat Immunol (2010) 2.68
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity (2010) 2.54
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol (2001) 2.51
Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol (2012) 2.49
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med (2006) 2.43
T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci U S A (2010) 2.41
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun (2008) 2.35
Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2004) 2.34
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30